Previous close | 15.74 |
Open | 15.60 |
Bid | 15.53 x 100 |
Ask | 15.63 x 200 |
Day's range | 15.43 - 16.15 |
52-week range | 3.94 - 17.42 |
Volume | |
Avg. volume | 459,035 |
Market cap | 782.373M |
Beta (5Y monthly) | 1.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.74 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 20.15 |
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus R2 was well tolerated with a safety profile similar to historical R2– The combination achieved promising initial activity with a best overall response rate (“ORR”) of 94% and a complete response rate (“CRR”) of 83% in patients with indolent R/R B-NHL (R2 historical CRR benchmark is 34%) SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWI